Bringing 3 Significant Events Under 1 Roof!
The Pharmaceutical Congress China, part of IBC’s PharmaCon Series, recognizes the importance of regulation, clinical operation efficiencies, tackling pharmaceutical compliance issues and bringing products and services successfully in the market in China’s rapidly advancing pharmaceutical industry.
Following our past four highly successful events, this event focuses on “A Critical Guide for Successfully Conducting “6th Annual Clinical Trials Summit 2015” It gives me great pleasure in welcoming all of you to The Virtue Insight’s “6th Annual Clinical Trials Summit 2015”.
This document provides information about the International Implantable and Interventional Medical Devices Emerging Technology Application Conference that will take place July 21-22, 2016 in Suzhou, China. The conference will focus on 4 themes: orthopedics, cardiovascular, orthodontics, and 3D printing/tissue engineering. It will include presentations from industry experts and regulators on the latest technologies, regulations, and market trends. Attendees will be able to network, see new product demonstrations, and tour local medical device manufacturing facilities. Over 200 people from various roles in medical device companies and related organizations are expected to attend.
Biologics World Taiwan 2016 (email me at justin.dejesus@imapac.com) Justin Barin de Jesus
The ONLY biopharmaceutical
gathering in Taiwan
Emphasizes on new business collaborations, demonstrate state-of-the-art developments and to propel Taiwan's biotech firms onto the world stage.
This document provides information about the 5th Pharmacovigilance Congregation conference taking place on November 20th, 2013 in Mumbai, India. The conference will discuss ensuring safer drugs reach the market through analyzing developments in pharmacovigilance, drug safety, and risk management. It will feature keynote speakers from various pharmaceutical companies and overviews of the latest challenges and opportunities in pharmacovigilance. The event aims to provide a platform for stakeholders to discuss best practices and advancing pharmacovigilance in India.
Greetings from Virtue Insight,
I am happy to invite you and your colleagues to be a sponsor/ delegate for our upcoming “7th Annual Clinical Trials Summit 2016” The conference will Be held on 14th May 2016, The Lalit Hotel, Mumbai, India.
Following our past six highly successful events, this event focuses on “A Critical Guide for Successfully Conducting “7th Annual Clinical Trials Summit 2016” It gives me great pleasure in welcoming all of you to The Virtue Insight’s “7th Annual Clinical Trials Summit 2016”. I wish and pray that all our efforts will be beneficial to our industries folks at large.
CONFIRMED SPEAKERS FROM :- Takeda Pharmaceuticals (UK), Clinical Research & Development, Cadila, Sanofi Aventis, Johnson & Johnson, GNH India, Clintech India, Boehringer Ingelheim, Reliance Life Sciences, Abbott, Glenmark Pharmaceuticals, Sanofi, Nishith Desai Associates, Novartis, Tata Consultancy Services, Janssen India (Pharmaceutical companies of Johnson & Johnson), SIRO Clinpharm, and few more..
CONFERENCE BOOKING DETAILS:-
• Standard Price (10th April 2016):- 1 or 2 Delegates - (INR 7,000 + Tax (14.5%) per delegate)
• Group Discounts – 3 or 4 Delegates - (INR 6,500 + Tax (14.5%) per delegate)
• Group Discounts – 5 and above Delegates - (INR 5,500 + Tax (14.5%) per delegate)
• Conference Sponsor & Exhibition Stall - Should you wish to Sponsor, or purchase a Exhibition Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to TEL: + 91 9171350244 or deepak@virtueinsight.co.in, deepakrajvirtueinsight@gmail.com
In case you or any of your colleagues might be interested in participating in the same, please let me know and I will be happy to call you and help you with the registration.
Thank you for your time and consideration. I look forward to hearing from you.
PS: - Please refer your friends or colleagues by forwarding this email to anyone you think may benefit from it.
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
The document discusses key aspects of clinical trial strategy and design. It covers the different phases of clinical trials (Phase I, II, III) and provides guidance on optimizing trials at each phase. Phase I focuses on safety and dosing, Phase II evaluates efficacy and further safety, and Phase III confirms efficacy in a larger patient population. The document emphasizes establishing a detailed clinical development plan with timelines and costs to help guide development decisions and reduce risks.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
Following our past four highly successful events, this event focuses on “A Critical Guide for Successfully Conducting “6th Annual Clinical Trials Summit 2015” It gives me great pleasure in welcoming all of you to The Virtue Insight’s “6th Annual Clinical Trials Summit 2015”.
This document provides information about the International Implantable and Interventional Medical Devices Emerging Technology Application Conference that will take place July 21-22, 2016 in Suzhou, China. The conference will focus on 4 themes: orthopedics, cardiovascular, orthodontics, and 3D printing/tissue engineering. It will include presentations from industry experts and regulators on the latest technologies, regulations, and market trends. Attendees will be able to network, see new product demonstrations, and tour local medical device manufacturing facilities. Over 200 people from various roles in medical device companies and related organizations are expected to attend.
Biologics World Taiwan 2016 (email me at justin.dejesus@imapac.com) Justin Barin de Jesus
The ONLY biopharmaceutical
gathering in Taiwan
Emphasizes on new business collaborations, demonstrate state-of-the-art developments and to propel Taiwan's biotech firms onto the world stage.
This document provides information about the 5th Pharmacovigilance Congregation conference taking place on November 20th, 2013 in Mumbai, India. The conference will discuss ensuring safer drugs reach the market through analyzing developments in pharmacovigilance, drug safety, and risk management. It will feature keynote speakers from various pharmaceutical companies and overviews of the latest challenges and opportunities in pharmacovigilance. The event aims to provide a platform for stakeholders to discuss best practices and advancing pharmacovigilance in India.
Greetings from Virtue Insight,
I am happy to invite you and your colleagues to be a sponsor/ delegate for our upcoming “7th Annual Clinical Trials Summit 2016” The conference will Be held on 14th May 2016, The Lalit Hotel, Mumbai, India.
Following our past six highly successful events, this event focuses on “A Critical Guide for Successfully Conducting “7th Annual Clinical Trials Summit 2016” It gives me great pleasure in welcoming all of you to The Virtue Insight’s “7th Annual Clinical Trials Summit 2016”. I wish and pray that all our efforts will be beneficial to our industries folks at large.
CONFIRMED SPEAKERS FROM :- Takeda Pharmaceuticals (UK), Clinical Research & Development, Cadila, Sanofi Aventis, Johnson & Johnson, GNH India, Clintech India, Boehringer Ingelheim, Reliance Life Sciences, Abbott, Glenmark Pharmaceuticals, Sanofi, Nishith Desai Associates, Novartis, Tata Consultancy Services, Janssen India (Pharmaceutical companies of Johnson & Johnson), SIRO Clinpharm, and few more..
CONFERENCE BOOKING DETAILS:-
• Standard Price (10th April 2016):- 1 or 2 Delegates - (INR 7,000 + Tax (14.5%) per delegate)
• Group Discounts – 3 or 4 Delegates - (INR 6,500 + Tax (14.5%) per delegate)
• Group Discounts – 5 and above Delegates - (INR 5,500 + Tax (14.5%) per delegate)
• Conference Sponsor & Exhibition Stall - Should you wish to Sponsor, or purchase a Exhibition Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to TEL: + 91 9171350244 or deepak@virtueinsight.co.in, deepakrajvirtueinsight@gmail.com
In case you or any of your colleagues might be interested in participating in the same, please let me know and I will be happy to call you and help you with the registration.
Thank you for your time and consideration. I look forward to hearing from you.
PS: - Please refer your friends or colleagues by forwarding this email to anyone you think may benefit from it.
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
The document discusses key aspects of clinical trial strategy and design. It covers the different phases of clinical trials (Phase I, II, III) and provides guidance on optimizing trials at each phase. Phase I focuses on safety and dosing, Phase II evaluates efficacy and further safety, and Phase III confirms efficacy in a larger patient population. The document emphasizes establishing a detailed clinical development plan with timelines and costs to help guide development decisions and reduce risks.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
Road to commercial success –the target product profile basics part 1 ishan sh...Ishan Shukla
The document discusses the use and benefits of a Target Product Profile (TPP) in drug development. A TPP outlines development goals and desired product attributes, including sections that would appear on the drug label. It allows sponsors to minimize risks, streamline FDA interactions, and improve label content and development timelines. When used strategically, a TPP can facilitate planning, assessment of pitfalls, and communication among stakeholders to efficiently guide development from early stages through approval and commercialization.
1) The document summarizes the state of clinical research in India, including the growth of the domestic and global clinical trials market in India, drivers of industry change, and India's strengths that make it an attractive location for outsourcing clinical research.
2) Key points discussed include India having a large, diverse population and strong technical skills that help accelerate patient recruitment for clinical trials compared to other countries. Costs of conducting clinical research in India are also much lower.
3) Challenges discussed include the need to further streamline regulatory processes, improve site infrastructure and staff training, and ensure strong data privacy protections to gain client confidence in outsourcing to India.
Presentation for spbt 2013 meeting background and researchklaffy
The document discusses the changing context of medical practice and the need for pharmaceutical representatives to build value-based relationships with physicians. It provides guidance on how representatives can validate their clinical knowledge through sub-specialty certification programs. The document also summarizes research that found physicians are more likely to meet with representatives who have completed specialized training programs developed by medical societies. Finally, it outlines the structure and attributes of an ideal disease-state training program for representatives.
This document provides an overview of clinical research and the clinical trial process. It discusses the various phases of clinical trials from phase 1 to phase 4. Phase 1 trials assess safety in a small group of participants, while phase 2 trials provide preliminary efficacy and safety data in patients. Phase 3 trials further evaluate efficacy and monitor safety in a larger group of patients. Phase 4 trials collect additional safety and efficacy data after marketing approval. The document outlines the objectives and requirements of each phase of clinical trials and the overall goal of generating evidence about new treatments to improve human health.
This document discusses Contract Research Organizations (CROs) and their role in supporting pharmaceutical clinical trials. It provides the following key points:
- CROs are service organizations that conduct clinical trials and other drug development work on behalf of pharmaceutical companies. They help companies that lack sufficient resources or expertise to conduct all required trials themselves.
- Selecting the right CRO is important for a successful clinical trial. Sponsors should clearly define study specifications, evaluate a CRO's capabilities and compatibility, and consider cost. Ongoing management of the sponsor-CRO relationship also impacts success.
- Common issues like selecting an inappropriate CRO, unclear study specifications from the sponsor, or poor management can lead
Greetings from Virtue Insight,
I am happy to invite you and your colleagues to be a sponsor/ delegate for our upcoming “9th Pharmacovigilance 2015” The conference will Be held on 2nd September 2015, Kohinoor Continental Hotel, Mumbai, India. Please find the detailed agenda for the same with this email.
FMD:- + 91 9171350244 or deepak@virtueinsight.co.in, deepakrajvirtueinsight@gmail.com
The document discusses HTA processes in France for evaluating new medicines. The French HTA process involves evaluating clinical value (SMR), clinical added value (ASMR), target population size, cost-effectiveness and budget impact. Medicines can receive reimbursement from the national health fund based on these evaluations. The HTA process aims to reward medicines providing real medical progress based on improved efficacy, safety or convenience compared to existing options (ASMR) and being worth their cost (cost-effectiveness).
SMi Group's Adaptive Designs in Clinical Trials conferenceDale Butler
This document summarizes an upcoming conference on adaptive designs in clinical trials taking place from April 20-21, 2015 in London. The conference will focus on topics such as Bayesian adaptive designs, subgroup selection in clinical trials, integrating real-world patient data into adaptive trials, and designing biomarker-driven multi-arm multi-stage cancer trials. Speakers will discuss challenges with adaptive designs and their use in different therapeutic areas like neurodegenerative diseases. Participants can also register for optional half-day workshops on April 22nd focusing on Bayesian clinical trial designs and navigating international regulatory landscapes for adaptive trials.
This document discusses Contract Research Organizations (CROs) and their role in supporting pharmaceutical clinical trials. It provides the following key points:
- CROs are service organizations that conduct clinical trials and other drug development work on behalf of pharmaceutical companies. This outsourcing has grown as drug development has become more complex.
- When deciding whether and how to use a CRO, companies consider tactical, maximal, or strategic outsourcing based on their internal resources. Selecting the right CRO requires evaluating their capabilities, compatibility with the sponsor's needs, and costs.
- Managing the sponsor-CRO relationship is critical to ensure success. This involves clearly defining roles and responsibilities, establishing performance metrics,
This presentation gives the details about career opportunities in clinical research, clinical research courses available in India and clinical research training.
Just to remind you that registrations for our 18th Pharmacovigilance 2019 event, which is taking place at The Pestana Chelsea Bridge Hotel in London, UK on 27-28th Feb are closing soon.For more details email to dinesh@virtueinsightsummits.com
What’s NEW in 2015’s program?
• More case studies on successful commercialization
• Insights on developing biosimilars under new CFDA guideline
• Emerging business models in regulated and developing markets
• New and timely topics on:
o Valuating biosimilars investments
o Successful technology transfer
o Key criteria in gaining approval
Also, NEW Expert Faculty includes:
Dr Shin Jae Chang, Vice President, Celltrion, Korea
Ira Jacobs, Global Oncology Lead, Biosimilars, Pfizer, US
Paul Thomas, Business Unit Head – Biosimilars, Biocon, India
Dr. Martina A. Sersch, Global Clinical Lead, Oncology Global Development, APAC Biotherapeutics Lead, Genentech, Inc. / F. Hoffmann-La Roche Ltd.
Raj Kannan, Vice President, Commercial Head, Biosimilars, Merck, Switzerland
Huiguo (Forrest) Hu, General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co., Ltd, China
Ko Chung Lin, Chief Executive Officer, PharmaEssentia Corporation, Taiwan
Wen Yong, Vice Director, Drug Research Institutes, Biopharmaceutical Institute, Jiangsu AoSaiKang Pharmaceutical Co Ltd, China
http://www.biosimilarsasia.com
Guideline on patient safety and well being in clinical trialsTrialJoin
Patient safety is and should be the number one priority in clinical research. Human participants in a clinical trial are necessary in order to improve and develop new therapies for certain conditions and advance the understanding of how a condition can be treated. Such medical advancements wouldn’t be possible without human subjects as participants. However, even though we all know the importance of clinical trials in the advancement of medicine, most people still have some misconceptions regarding this topic.
The feeling of being treated as a ‘’guinea pig’’ and fear of potential risks and side effects are still common among patients who suffer from a certain condition. Such misinformation and misconceptions regarding clinical trials can unnecessarily prevent patients from finding a potential cure or relief, and can also decrease the number of enrolled patients in studies.
In order to clarify these misunderstandings, we’ve decided to tell you everything there is to know about patient safety in clinical trials. We hope that with this information we can help you to better understand patient safety in clinical trials so that you gain more insight and start considering clinical trials as valid options that can help you improve any condition.
Clinical Development Kp Is Ii 08 Dec2011MFinch3777
This document discusses the importance of clinical trial program evaluation and defining key performance indicators (KPIs) to measure success. It states that evaluation should start during program development to influence decision making and create a return on investment. Defining the correct KPIs allows for monitoring trial performance and efficiency. Tracking metrics can improve studies by identifying issues and implementing corrective actions. Evaluation provides data to assess outcomes and costs, and justify resources to stakeholders. The goal of evaluation is to support projects and help them succeed better than planned.
This document discusses common interview questions and answers related to clinical trial management jobs. It begins by defining key terms like clinical trials and their various types. It then addresses questions about participant eligibility, the trial process, informed consent, safety monitoring, and data management. Specific topics covered include trial phases, the purpose of placebos and control groups, adverse event reporting, and the responsibilities of clinical research coordinators.
Presentation: New pathway for complementary medicinesTGA Australia
An overview of recommendation thirty-nine from the Review of Medicines and Medical Devices Regulation relating to improving access to evidence based listed complementary medicines.
Visit : www.acriindia.com
ACRI is a leading pharmacovigilance training Institute in Bangalore.
ACRI creates a value add for every degree. Our PG course is diploma in clinical research and PG diploma in pharmavigilance are approved by the Mysore University. Graduates and Post Graduates and even PhDs have trained with us and got enviable positions in the Clinical Research Industry. ACRI supplements University training with Industry based training, coupled with hands-on internships and projects based on real case studies. The ACRI brand gives the individual the confidence and expertise to join the ever-growing workforce both in the country and abroad.
This document provides information about the IBC Oncology Asia conference happening from November 25-28, 2014 in Singapore. The conference will focus on clinical development and market access strategies for oncology drugs in Asia. It will feature speakers from pharmaceutical companies discussing topics like market trends, developing competitive pipelines, biosimilars, clinical trials, understanding oncologists, market access strategies, pricing and reimbursement. There will also be pre and post-conference workshops on oncology clinical trials, biosimilars, and pricing and reimbursement models. The conference aims to help attendees learn how to expedite oncology drug development and successfully access cancer drug markets in Asia.
This document provides an agenda for the IBC Life Sciences conference taking place August 26-29, 2014 in Singapore. The conference will feature over 25 R&D expert speakers and focus on licensing, M&A, regulations, investment opportunities, clinical trial development in Asia, intellectual property strategies, and more. Key panelists and speakers include representatives from Pfizer, Sanofi, GSK, and other major pharmaceutical companies. The agenda outlines presentations and panel discussions on topics like Asia's pharmaceutical market outlook, strategic partnerships, clinical trial risks in Southeast Asia, biosimilars and generics R&D, and driving drug innovation in the region.
Biopharma Production & Development Week 2015 Rita Barry
What’s New for 2015
- C-Level Panel: Cutting Edge Insights on China’s Growing Biotech Market
- China FDA Special Address
- 80+ Key Expert Speakers from Asia’s leading Pharma & Biotech
- 1 Joint Exhibition & Networking Area
- 4 Days of Expert Knowledge Sharing
- Revamped Program with New Special Focused Tracks & Sessions
With the growth and development of the biopharma industry and increasing changing legislations on areas like biosimilars, pediatric drug development and generic drugs in China and East Asia, now is the time for you to bring along your regulatory affairs teams to keep abreast of evolving regulatory environments and requirements at IBC’s 2nd Pharmaceutical Regulatory Summit in China.
http://www.pharmaregulatoryasia.com/
Road to commercial success –the target product profile basics part 1 ishan sh...Ishan Shukla
The document discusses the use and benefits of a Target Product Profile (TPP) in drug development. A TPP outlines development goals and desired product attributes, including sections that would appear on the drug label. It allows sponsors to minimize risks, streamline FDA interactions, and improve label content and development timelines. When used strategically, a TPP can facilitate planning, assessment of pitfalls, and communication among stakeholders to efficiently guide development from early stages through approval and commercialization.
1) The document summarizes the state of clinical research in India, including the growth of the domestic and global clinical trials market in India, drivers of industry change, and India's strengths that make it an attractive location for outsourcing clinical research.
2) Key points discussed include India having a large, diverse population and strong technical skills that help accelerate patient recruitment for clinical trials compared to other countries. Costs of conducting clinical research in India are also much lower.
3) Challenges discussed include the need to further streamline regulatory processes, improve site infrastructure and staff training, and ensure strong data privacy protections to gain client confidence in outsourcing to India.
Presentation for spbt 2013 meeting background and researchklaffy
The document discusses the changing context of medical practice and the need for pharmaceutical representatives to build value-based relationships with physicians. It provides guidance on how representatives can validate their clinical knowledge through sub-specialty certification programs. The document also summarizes research that found physicians are more likely to meet with representatives who have completed specialized training programs developed by medical societies. Finally, it outlines the structure and attributes of an ideal disease-state training program for representatives.
This document provides an overview of clinical research and the clinical trial process. It discusses the various phases of clinical trials from phase 1 to phase 4. Phase 1 trials assess safety in a small group of participants, while phase 2 trials provide preliminary efficacy and safety data in patients. Phase 3 trials further evaluate efficacy and monitor safety in a larger group of patients. Phase 4 trials collect additional safety and efficacy data after marketing approval. The document outlines the objectives and requirements of each phase of clinical trials and the overall goal of generating evidence about new treatments to improve human health.
This document discusses Contract Research Organizations (CROs) and their role in supporting pharmaceutical clinical trials. It provides the following key points:
- CROs are service organizations that conduct clinical trials and other drug development work on behalf of pharmaceutical companies. They help companies that lack sufficient resources or expertise to conduct all required trials themselves.
- Selecting the right CRO is important for a successful clinical trial. Sponsors should clearly define study specifications, evaluate a CRO's capabilities and compatibility, and consider cost. Ongoing management of the sponsor-CRO relationship also impacts success.
- Common issues like selecting an inappropriate CRO, unclear study specifications from the sponsor, or poor management can lead
Greetings from Virtue Insight,
I am happy to invite you and your colleagues to be a sponsor/ delegate for our upcoming “9th Pharmacovigilance 2015” The conference will Be held on 2nd September 2015, Kohinoor Continental Hotel, Mumbai, India. Please find the detailed agenda for the same with this email.
FMD:- + 91 9171350244 or deepak@virtueinsight.co.in, deepakrajvirtueinsight@gmail.com
The document discusses HTA processes in France for evaluating new medicines. The French HTA process involves evaluating clinical value (SMR), clinical added value (ASMR), target population size, cost-effectiveness and budget impact. Medicines can receive reimbursement from the national health fund based on these evaluations. The HTA process aims to reward medicines providing real medical progress based on improved efficacy, safety or convenience compared to existing options (ASMR) and being worth their cost (cost-effectiveness).
SMi Group's Adaptive Designs in Clinical Trials conferenceDale Butler
This document summarizes an upcoming conference on adaptive designs in clinical trials taking place from April 20-21, 2015 in London. The conference will focus on topics such as Bayesian adaptive designs, subgroup selection in clinical trials, integrating real-world patient data into adaptive trials, and designing biomarker-driven multi-arm multi-stage cancer trials. Speakers will discuss challenges with adaptive designs and their use in different therapeutic areas like neurodegenerative diseases. Participants can also register for optional half-day workshops on April 22nd focusing on Bayesian clinical trial designs and navigating international regulatory landscapes for adaptive trials.
This document discusses Contract Research Organizations (CROs) and their role in supporting pharmaceutical clinical trials. It provides the following key points:
- CROs are service organizations that conduct clinical trials and other drug development work on behalf of pharmaceutical companies. This outsourcing has grown as drug development has become more complex.
- When deciding whether and how to use a CRO, companies consider tactical, maximal, or strategic outsourcing based on their internal resources. Selecting the right CRO requires evaluating their capabilities, compatibility with the sponsor's needs, and costs.
- Managing the sponsor-CRO relationship is critical to ensure success. This involves clearly defining roles and responsibilities, establishing performance metrics,
This presentation gives the details about career opportunities in clinical research, clinical research courses available in India and clinical research training.
Just to remind you that registrations for our 18th Pharmacovigilance 2019 event, which is taking place at The Pestana Chelsea Bridge Hotel in London, UK on 27-28th Feb are closing soon.For more details email to dinesh@virtueinsightsummits.com
What’s NEW in 2015’s program?
• More case studies on successful commercialization
• Insights on developing biosimilars under new CFDA guideline
• Emerging business models in regulated and developing markets
• New and timely topics on:
o Valuating biosimilars investments
o Successful technology transfer
o Key criteria in gaining approval
Also, NEW Expert Faculty includes:
Dr Shin Jae Chang, Vice President, Celltrion, Korea
Ira Jacobs, Global Oncology Lead, Biosimilars, Pfizer, US
Paul Thomas, Business Unit Head – Biosimilars, Biocon, India
Dr. Martina A. Sersch, Global Clinical Lead, Oncology Global Development, APAC Biotherapeutics Lead, Genentech, Inc. / F. Hoffmann-La Roche Ltd.
Raj Kannan, Vice President, Commercial Head, Biosimilars, Merck, Switzerland
Huiguo (Forrest) Hu, General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co., Ltd, China
Ko Chung Lin, Chief Executive Officer, PharmaEssentia Corporation, Taiwan
Wen Yong, Vice Director, Drug Research Institutes, Biopharmaceutical Institute, Jiangsu AoSaiKang Pharmaceutical Co Ltd, China
http://www.biosimilarsasia.com
Guideline on patient safety and well being in clinical trialsTrialJoin
Patient safety is and should be the number one priority in clinical research. Human participants in a clinical trial are necessary in order to improve and develop new therapies for certain conditions and advance the understanding of how a condition can be treated. Such medical advancements wouldn’t be possible without human subjects as participants. However, even though we all know the importance of clinical trials in the advancement of medicine, most people still have some misconceptions regarding this topic.
The feeling of being treated as a ‘’guinea pig’’ and fear of potential risks and side effects are still common among patients who suffer from a certain condition. Such misinformation and misconceptions regarding clinical trials can unnecessarily prevent patients from finding a potential cure or relief, and can also decrease the number of enrolled patients in studies.
In order to clarify these misunderstandings, we’ve decided to tell you everything there is to know about patient safety in clinical trials. We hope that with this information we can help you to better understand patient safety in clinical trials so that you gain more insight and start considering clinical trials as valid options that can help you improve any condition.
Clinical Development Kp Is Ii 08 Dec2011MFinch3777
This document discusses the importance of clinical trial program evaluation and defining key performance indicators (KPIs) to measure success. It states that evaluation should start during program development to influence decision making and create a return on investment. Defining the correct KPIs allows for monitoring trial performance and efficiency. Tracking metrics can improve studies by identifying issues and implementing corrective actions. Evaluation provides data to assess outcomes and costs, and justify resources to stakeholders. The goal of evaluation is to support projects and help them succeed better than planned.
This document discusses common interview questions and answers related to clinical trial management jobs. It begins by defining key terms like clinical trials and their various types. It then addresses questions about participant eligibility, the trial process, informed consent, safety monitoring, and data management. Specific topics covered include trial phases, the purpose of placebos and control groups, adverse event reporting, and the responsibilities of clinical research coordinators.
Presentation: New pathway for complementary medicinesTGA Australia
An overview of recommendation thirty-nine from the Review of Medicines and Medical Devices Regulation relating to improving access to evidence based listed complementary medicines.
Visit : www.acriindia.com
ACRI is a leading pharmacovigilance training Institute in Bangalore.
ACRI creates a value add for every degree. Our PG course is diploma in clinical research and PG diploma in pharmavigilance are approved by the Mysore University. Graduates and Post Graduates and even PhDs have trained with us and got enviable positions in the Clinical Research Industry. ACRI supplements University training with Industry based training, coupled with hands-on internships and projects based on real case studies. The ACRI brand gives the individual the confidence and expertise to join the ever-growing workforce both in the country and abroad.
This document provides information about the IBC Oncology Asia conference happening from November 25-28, 2014 in Singapore. The conference will focus on clinical development and market access strategies for oncology drugs in Asia. It will feature speakers from pharmaceutical companies discussing topics like market trends, developing competitive pipelines, biosimilars, clinical trials, understanding oncologists, market access strategies, pricing and reimbursement. There will also be pre and post-conference workshops on oncology clinical trials, biosimilars, and pricing and reimbursement models. The conference aims to help attendees learn how to expedite oncology drug development and successfully access cancer drug markets in Asia.
This document provides an agenda for the IBC Life Sciences conference taking place August 26-29, 2014 in Singapore. The conference will feature over 25 R&D expert speakers and focus on licensing, M&A, regulations, investment opportunities, clinical trial development in Asia, intellectual property strategies, and more. Key panelists and speakers include representatives from Pfizer, Sanofi, GSK, and other major pharmaceutical companies. The agenda outlines presentations and panel discussions on topics like Asia's pharmaceutical market outlook, strategic partnerships, clinical trial risks in Southeast Asia, biosimilars and generics R&D, and driving drug innovation in the region.
Biopharma Production & Development Week 2015 Rita Barry
What’s New for 2015
- C-Level Panel: Cutting Edge Insights on China’s Growing Biotech Market
- China FDA Special Address
- 80+ Key Expert Speakers from Asia’s leading Pharma & Biotech
- 1 Joint Exhibition & Networking Area
- 4 Days of Expert Knowledge Sharing
- Revamped Program with New Special Focused Tracks & Sessions
With the growth and development of the biopharma industry and increasing changing legislations on areas like biosimilars, pediatric drug development and generic drugs in China and East Asia, now is the time for you to bring along your regulatory affairs teams to keep abreast of evolving regulatory environments and requirements at IBC’s 2nd Pharmaceutical Regulatory Summit in China.
http://www.pharmaregulatoryasia.com/
Dr. Samuel Dyer will be moderating the 2nd Annual Medical Affairs Leaders Forum Asia in Hong Kong on August 5th-6th, 2014.
Dr. Samuel Dyer will also be speaking at the event and will represent the Medical Science Liaison Society.
2nd Annual Oncology Asia
Date: 7 – 9 September 2015 | Sheraton Miyako, Tokyo, Japan
www.oncologyasia.com
The 2nd Annual Oncology Asia zeroes in on the latest cutting edge developments in oncology drug discovery and late phase strategies to get oncology drugs to market faster! Under the Drug Discovery track, this conference will discuss latest immune checkpoint inhibitor combinations, preclinical development trends, novel biomarkers and oncology drug development case studies in Asia. Under the late phase track, it will discuss pricing for success, global and regional commercialization case studies, healthcare policy updates and pricing for success.
Find out about the latest drug discovery trends along with latest strategies for global and regional commercialization at the ONLY senior industry gathering focused on advancing cutting edge oncology R&D and commercialization strategies for Asia in Tokyo, Japan!
The document discusses future prospects and challenges for biotherapeutics. It begins by defining biotherapeutics as products produced using living cells or organisms, such as recombinant hormones, vaccines, monoclonal antibodies, growth factors, and gene and cell therapies. It then contrasts biotherapeutics, biosimilars, and generics. The document outlines the complex manufacturing process for biotherapeutics and challenges in characterizing their large, complex structures. It concludes by discussing switching and interchangeability studies required to demonstrate a biosimilar is as safe and effective as the reference biologic.
Why you should attend:
1. Learn from in-depth case studies on strategic partnering and effective collaboration
2. Explore new business opportunities and strategies to reach the biosimilars market in the region
3. Gain insights into the regulatory landscape for biosimilars in China, India, Korea, Taiwan and more
4. Gather the latest market intelligence and analysis and identify new trends and opportunities in Biosimilars R&D, contract manufacturing and commercialization in Asia
报名参加的五大理由
1. 深入学习有关与亚洲公司建立战略合作和有效协作的案例研究
2. 探索新的商机和战略,以便进入当地的生物仿制药市场
3. 深入了解中国、印度、韩国、台湾以及更多国家或地区的生物仿制药监管形势
4. 收集最新的市场情报和分析,确定生物仿制药研发、合同制造和商业化在亚洲的新趋势和机会
Hear about:
Biopharma Regulatory Updates and Development
Victoria Elegant, VP Medical & Regulatory Affairs, Baxter, China
Andrea Laslop, Head of Scientific Office, Austrian Agency for Food and Health Safety, Austrian Member, European Medicines Agency
Arvind Mishra, Global Head of Quality & Regulatory & Head of Strategic Business Unit, Biologicals, Cadilla Pharmaceutical, India
Advances in Biosimilars R&D
Jeffrey Su, CSO, Cytovance Biologics, USA
Wenzhi Tian, CEO, Huabo Biopharma, China
Ming Wang, President and COO, Gan & Lee Pharmaceuticals, China
Feng Li, CEO, Beijing Mabworks, China
Shaligram Rane, Vice President for Quality, Intas Pharmaceuticals, India
Understanding Obstacles and Hurdles for Entering the Biosimilars Market
Khai Meng Ang, Vice President Asia, Hospira, China
Jason Li, Senior Director, Genor Biopharma, China
Sachidananda Moorthy, Vice President - Clinical Research, Medical and Regulatory Affairs, Avesthagen, India
Sameer Agarwal, Senior Vice President, Business Center Strategic Marketing, Business Unit Generic Drugs & Standard Solutions, Fresenius Kabi, Germany
What can Asia Learn from Global Biosimilars Development and Litigation?
Li Cai, Regional R&D Counsel, Pfizer, China
Vivek Mittal, Head – Legal, Lupin, India
Viren Mahurkar, Managing Director, HitechnRock Advisors, Singapore
http://www.biosimilarsasia.com
Pre-Conference Special Focus Day, 20 May 2014
Clinical Development for Biosimilars
Post-Conference Workshops, 23 May 2014
A: Challenges in Demonstrating Biosimilarity and Interchangeability of Biosimilar Products
B: Successfully Bringing Biosimilars to Market
会前特别关注日,2014 年 5 月 20 日
生物仿制药的临床开发
会后研讨会,2014 年 5 月 23 日
A:在展示生物仿制药产品的生物相似性和可互换性方面所面临的挑战
B:成功地将生物仿制药推向市场
Pharmaceutical Quality - The Office ofAjaz Hussain
The keynote address at the Fall meeting of the CPPR Industrial Advisory Board and the Site Directors held yesterday (27 October 2014) at Purdue University. The talk provides a perspective on the recent organizational changes announced by FDA CDER - the Office of Pharmaceutical Quality.
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...Sardegna Ricerche
L'intervento di Luca Pani (professore Ordinario di Psichiatria Clinica, Università di Miami) in occasione dell'evento "Il valore della ricerca biomedica" che si è tenuto a Pula (CA) il 3 aprile 2019.
Following our past four highly successful events, this event focuses on “A Critical Guide for Successfully Conducting “6th Annual Clinical Trials Summit 2015” It gives me great pleasure in welcoming all of you to The Virtue Insight’s “6th Annual Clinical Trials Summit 2015”.
Lior - Improving Medication Safety in RadiologyLior Molvin
This webinar explores medication safety issues in radiology settings. It will discuss cases where errors have occurred and risk reduction strategies. Nationally recognized experts will address topics like safe contrast use, proper labeling, expiration dating, and patient identification. Faculty will examine a new Imaging Bulk Package for contrast approved by the FDA and regulatory/Joint Commission requirements for contrast and medication use in radiology. The goal is for pharmacists and radiologic technologists to understand medication ordering, storage, preparation and use in radiology; differentiate new Imaging Bulk Packages from Pharmacy Bulk Packages; and identify system causes of radiology medication errors to prioritize prevention strategies.
Advanced Analytics for Clinical Data Full Event GuidePfizer
This document provides information about the "Advanced Analytics for Clinical Data" conference to be held February 1-2, 2017 in San Francisco. The conference will focus on applying advanced analytics and data-driven methodologies in clinical research and drug development. It will feature presentations from experts in clinical data science from major pharmaceutical companies. Topics will include implementing analytics from areas like biostatistics, omics, and wearables. Attendees will learn how to extract value from large datasets and new sources of data. The agenda also includes panels on leveraging big data in clinical trials and evolving the role of clinical data management.
This document provides a framework called Process Analytical Technology (PAT) to encourage innovation in pharmaceutical development, manufacturing, and quality assurance. The PAT framework has two components: 1) scientific principles and tools to support innovation through increased process understanding; and 2) a strategy for regulatory implementation to accommodate innovation through a collaborative approach between industry and regulators. The goals are to ensure product quality, encourage use of new technologies, apply regulations consistently, and use resources efficiently to address significant health risks.
The document summarizes an upcoming conference on patient-centered clinical trials taking place October 19-20, 2015 in Philadelphia. It will feature over 30 industry experts and leaders from pharmaceutical companies such as Johnson & Johnson, Pfizer, AstraZeneca, and Google. The goal of the conference is to discuss how to better involve patients in the design and conduct of clinical trials to improve recruitment, retention, and trial success by putting the patient voice at the core. It will provide a forum for stakeholders from industry, patient advocacy groups, and regulators to collaborate on developing a framework for patient engagement in clinical trials.
International and regional experts coming together
to discuss strategies and opportunities in the Medical
Affairs function
• Unique insights and case studies on experiences in
the Asia market, successful programmes and best
practices
• Detailed and practical workshop to complement
your learning and networking experience
This document provides an agenda and materials for a symposium titled "Improving Medication Safety in the Radiology Setting". The agenda includes presentations on medication administration systems and medications used in radiology, medication safety issues and strategies in radiology, and regulatory and accreditation requirements related to medication use in radiology. The objectives are to describe how medications are handled in radiology, explain new FDA classifications for contrast, identify medication errors in radiology, discuss safety strategies, and describe regulatory standards. Faculty include experts from the Institute for Safe Medication Practices who will discuss actual error cases and risk reduction.
pharmaceutical companies spend money to develop appropriate literature to market their new drugs. ppt throws light on how healthy skepticism will help the health care practitioners to interpret the literature presented by the medical representatives
10 most trusted clinical laboratories in 2021Merry D'souza
To honor the diligent services of clinical laboratories, we came up with this edition of Insights Care - 10 Most Trusted Clinical Laboratories in 2021.
This document summarizes a 3-day conference on market access in Latin America for pharmaceutical and medical device companies. Day 1 focuses on the Latin American payer and health technology assessment summit. Day 2 has two streams, one on pharmaceutical market access and one on medical device market access and commercialization. Day 3 is on evidence development in Latin America. There will be over 26 presentations from regional market access leaders, including representatives from health technology assessment agencies, payers, pharmaceutical and medical device companies, policy researchers, and consulting firms. The conference aims to help companies demonstrate product value, understand different market approaches and barriers, and develop strategies for partnering with customers in the complex and dynamic Latin American healthcare markets.
The document provides an overview of careers in the biopharmaceutical industry. It describes the long process of developing new drugs, which involves identifying drug targets, designing and testing compounds, conducting preclinical and clinical trials, gaining regulatory approval, and post-launch monitoring. Many roles are needed across research, development, manufacturing, regulatory affairs, sales, and other functions. The average time to get a new drug to market is 14 years and over $1 billion.
Similar to Pharmaceutical Congress China 29-30 March 2016 (20)
The debris of the ‘last major merger’ is dynamically youngSérgio Sacani
The Milky Way’s (MW) inner stellar halo contains an [Fe/H]-rich component with highly eccentric orbits, often referred to as the
‘last major merger.’ Hypotheses for the origin of this component include Gaia-Sausage/Enceladus (GSE), where the progenitor
collided with the MW proto-disc 8–11 Gyr ago, and the Virgo Radial Merger (VRM), where the progenitor collided with the
MW disc within the last 3 Gyr. These two scenarios make different predictions about observable structure in local phase space,
because the morphology of debris depends on how long it has had to phase mix. The recently identified phase-space folds in Gaia
DR3 have positive caustic velocities, making them fundamentally different than the phase-mixed chevrons found in simulations
at late times. Roughly 20 per cent of the stars in the prograde local stellar halo are associated with the observed caustics. Based
on a simple phase-mixing model, the observed number of caustics are consistent with a merger that occurred 1–2 Gyr ago.
We also compare the observed phase-space distribution to FIRE-2 Latte simulations of GSE-like mergers, using a quantitative
measurement of phase mixing (2D causticality). The observed local phase-space distribution best matches the simulated data
1–2 Gyr after collision, and certainly not later than 3 Gyr. This is further evidence that the progenitor of the ‘last major merger’
did not collide with the MW proto-disc at early times, as is thought for the GSE, but instead collided with the MW disc within
the last few Gyr, consistent with the body of work surrounding the VRM.
Current Ms word generated power point presentation covers major details about the micronuclei test. It's significance and assays to conduct it. It is used to detect the micronuclei formation inside the cells of nearly every multicellular organism. It's formation takes place during chromosomal sepration at metaphase.
EWOCS-I: The catalog of X-ray sources in Westerlund 1 from the Extended Weste...Sérgio Sacani
Context. With a mass exceeding several 104 M⊙ and a rich and dense population of massive stars, supermassive young star clusters
represent the most massive star-forming environment that is dominated by the feedback from massive stars and gravitational interactions
among stars.
Aims. In this paper we present the Extended Westerlund 1 and 2 Open Clusters Survey (EWOCS) project, which aims to investigate
the influence of the starburst environment on the formation of stars and planets, and on the evolution of both low and high mass stars.
The primary targets of this project are Westerlund 1 and 2, the closest supermassive star clusters to the Sun.
Methods. The project is based primarily on recent observations conducted with the Chandra and JWST observatories. Specifically,
the Chandra survey of Westerlund 1 consists of 36 new ACIS-I observations, nearly co-pointed, for a total exposure time of 1 Msec.
Additionally, we included 8 archival Chandra/ACIS-S observations. This paper presents the resulting catalog of X-ray sources within
and around Westerlund 1. Sources were detected by combining various existing methods, and photon extraction and source validation
were carried out using the ACIS-Extract software.
Results. The EWOCS X-ray catalog comprises 5963 validated sources out of the 9420 initially provided to ACIS-Extract, reaching a
photon flux threshold of approximately 2 × 10−8 photons cm−2
s
−1
. The X-ray sources exhibit a highly concentrated spatial distribution,
with 1075 sources located within the central 1 arcmin. We have successfully detected X-ray emissions from 126 out of the 166 known
massive stars of the cluster, and we have collected over 71 000 photons from the magnetar CXO J164710.20-455217.
Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...Ana Luísa Pinho
Functional Magnetic Resonance Imaging (fMRI) provides means to characterize brain activations in response to behavior. However, cognitive neuroscience has been limited to group-level effects referring to the performance of specific tasks. To obtain the functional profile of elementary cognitive mechanisms, the combination of brain responses to many tasks is required. Yet, to date, both structural atlases and parcellation-based activations do not fully account for cognitive function and still present several limitations. Further, they do not adapt overall to individual characteristics. In this talk, I will give an account of deep-behavioral phenotyping strategies, namely data-driven methods in large task-fMRI datasets, to optimize functional brain-data collection and improve inference of effects-of-interest related to mental processes. Key to this approach is the employment of fast multi-functional paradigms rich on features that can be well parametrized and, consequently, facilitate the creation of psycho-physiological constructs to be modelled with imaging data. Particular emphasis will be given to music stimuli when studying high-order cognitive mechanisms, due to their ecological nature and quality to enable complex behavior compounded by discrete entities. I will also discuss how deep-behavioral phenotyping and individualized models applied to neuroimaging data can better account for the subject-specific organization of domain-general cognitive systems in the human brain. Finally, the accumulation of functional brain signatures brings the possibility to clarify relationships among tasks and create a univocal link between brain systems and mental functions through: (1) the development of ontologies proposing an organization of cognitive processes; and (2) brain-network taxonomies describing functional specialization. To this end, tools to improve commensurability in cognitive science are necessary, such as public repositories, ontology-based platforms and automated meta-analysis tools. I will thus discuss some brain-atlasing resources currently under development, and their applicability in cognitive as well as clinical neuroscience.
Travis Hills' Endeavors in Minnesota: Fostering Environmental and Economic Pr...Travis Hills MN
Travis Hills of Minnesota developed a method to convert waste into high-value dry fertilizer, significantly enriching soil quality. By providing farmers with a valuable resource derived from waste, Travis Hills helps enhance farm profitability while promoting environmental stewardship. Travis Hills' sustainable practices lead to cost savings and increased revenue for farmers by improving resource efficiency and reducing waste.
ANAMOLOUS SECONDARY GROWTH IN DICOT ROOTS.pptxRASHMI M G
Abnormal or anomalous secondary growth in plants. It defines secondary growth as an increase in plant girth due to vascular cambium or cork cambium. Anomalous secondary growth does not follow the normal pattern of a single vascular cambium producing xylem internally and phloem externally.
The ability to recreate computational results with minimal effort and actionable metrics provides a solid foundation for scientific research and software development. When people can replicate an analysis at the touch of a button using open-source software, open data, and methods to assess and compare proposals, it significantly eases verification of results, engagement with a diverse range of contributors, and progress. However, we have yet to fully achieve this; there are still many sociotechnical frictions.
Inspired by David Donoho's vision, this talk aims to revisit the three crucial pillars of frictionless reproducibility (data sharing, code sharing, and competitive challenges) with the perspective of deep software variability.
Our observation is that multiple layers — hardware, operating systems, third-party libraries, software versions, input data, compile-time options, and parameters — are subject to variability that exacerbates frictions but is also essential for achieving robust, generalizable results and fostering innovation. I will first review the literature, providing evidence of how the complex variability interactions across these layers affect qualitative and quantitative software properties, thereby complicating the reproduction and replication of scientific studies in various fields.
I will then present some software engineering and AI techniques that can support the strategic exploration of variability spaces. These include the use of abstractions and models (e.g., feature models), sampling strategies (e.g., uniform, random), cost-effective measurements (e.g., incremental build of software configurations), and dimensionality reduction methods (e.g., transfer learning, feature selection, software debloating).
I will finally argue that deep variability is both the problem and solution of frictionless reproducibility, calling the software science community to develop new methods and tools to manage variability and foster reproducibility in software systems.
Exposé invité Journées Nationales du GDR GPL 2024
When I was asked to give a companion lecture in support of ‘The Philosophy of Science’ (https://shorturl.at/4pUXz) I decided not to walk through the detail of the many methodologies in order of use. Instead, I chose to employ a long standing, and ongoing, scientific development as an exemplar. And so, I chose the ever evolving story of Thermodynamics as a scientific investigation at its best.
Conducted over a period of >200 years, Thermodynamics R&D, and application, benefitted from the highest levels of professionalism, collaboration, and technical thoroughness. New layers of application, methodology, and practice were made possible by the progressive advance of technology. In turn, this has seen measurement and modelling accuracy continually improved at a micro and macro level.
Perhaps most importantly, Thermodynamics rapidly became a primary tool in the advance of applied science/engineering/technology, spanning micro-tech, to aerospace and cosmology. I can think of no better a story to illustrate the breadth of scientific methodologies and applications at their best.
The use of Nauplii and metanauplii artemia in aquaculture (brine shrimp).pptxMAGOTI ERNEST
Although Artemia has been known to man for centuries, its use as a food for the culture of larval organisms apparently began only in the 1930s, when several investigators found that it made an excellent food for newly hatched fish larvae (Litvinenko et al., 2023). As aquaculture developed in the 1960s and ‘70s, the use of Artemia also became more widespread, due both to its convenience and to its nutritional value for larval organisms (Arenas-Pardo et al., 2024). The fact that Artemia dormant cysts can be stored for long periods in cans, and then used as an off-the-shelf food requiring only 24 h of incubation makes them the most convenient, least labor-intensive, live food available for aquaculture (Sorgeloos & Roubach, 2021). The nutritional value of Artemia, especially for marine organisms, is not constant, but varies both geographically and temporally. During the last decade, however, both the causes of Artemia nutritional variability and methods to improve poorquality Artemia have been identified (Loufi et al., 2024).
Brine shrimp (Artemia spp.) are used in marine aquaculture worldwide. Annually, more than 2,000 metric tons of dry cysts are used for cultivation of fish, crustacean, and shellfish larva. Brine shrimp are important to aquaculture because newly hatched brine shrimp nauplii (larvae) provide a food source for many fish fry (Mozanzadeh et al., 2021). Culture and harvesting of brine shrimp eggs represents another aspect of the aquaculture industry. Nauplii and metanauplii of Artemia, commonly known as brine shrimp, play a crucial role in aquaculture due to their nutritional value and suitability as live feed for many aquatic species, particularly in larval stages (Sorgeloos & Roubach, 2021).
This presentation explores a brief idea about the structural and functional attributes of nucleotides, the structure and function of genetic materials along with the impact of UV rays and pH upon them.
hematic appreciation test is a psychological assessment tool used to measure an individual's appreciation and understanding of specific themes or topics. This test helps to evaluate an individual's ability to connect different ideas and concepts within a given theme, as well as their overall comprehension and interpretation skills. The results of the test can provide valuable insights into an individual's cognitive abilities, creativity, and critical thinking skills
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
Pharmaceutical Congress China 29-30 March 2016
1. Produced by:
Life
Sciences
29 - 30 March 2016
Grand Hyatt Shanghai
CHINA
Co-Located Events:
The leading event that brings together
China’s leading pharmaceutical
companies and industry in one place!
Li Chen
CEO,
Hua Medicine,
China
Xian Ping Lu
CEO & CSO,
Shenzhen
Chipscreen
Biosciences, China
Friedhelm Blobel
CEO,
SciClone
Pharmaceuticals,
USA & China
Ming-Chu Hsu
Chairman of the
Board & CEO,
TaiGen
Biotechnology,
Taiwan
Weikang Tao
CEO, R&D Centre,
Shanghai Hengrui
Medicine, China
Yin Xiang Wang
CEO & CSO,
Betta
Pharmaceuticals,
China
Ming-Qiang
Zhang
Corporate Vice-
President, Research &
Development,
Amgen, China
Joan Shen
Vice President,
Development Head
ChinaR&DandScientific
Affairs, Janssen
Pharmaceuticals,
Johnson & Johnson,
China
Steffanie Lim-Ho
VicePresident,
Ethics&Compliance,
Lilly, China
Masood Ahmed
Vice President,
Regional Compliance
Officer
Asia & JPAC,
Sanofi Group,
Singapore
Associate Sponsor: Session Spotlight Sponsor:Bronze Sponsor:
International Marketing
Partner:
CHINA
Li Yan
Vice President, Head
Unit Physician,
Oncology R&D,
GlaxoSmithKline
Pharmaceuticals,
USA
Latest Updates on China’s
Pharmaceutical regulation and
market trends
Practical Case Studies on the
Ground in China
75+ renowned speakers from
the pharmaceutical industry
1 shared exhibition room to
showcase latest technology and
services
4 days of expert knowledge
sharing
TOP REASONS
TO ATTEND
www.pharmaconchina.com
Shanghai Food & Drug
Administration (SFDA)
Taiwan Food & Drug
Administration (TFDA)
Keynote Regulator Sessions from:
Industry Experts Include:
Ye Hua
Senior Vice President,
ClinicalDevelopmentand
Regulatory Affairs,
Hutchison
Medipharma, China
Optimize
your Time & Money
with a Gold Pass
- Full Access to
ALL Events is Possible!
Gold Sponsor:
Exhibitors:
2. 9.00 R&D Market Opportunities & Challenges
• Current drug development scenario in China vs. theWest
• How do you bring products to market quickly and cost effectively in China?
• Can the local Chinese pharma companies sustain R&D innovation?
• Encouraging innovation and healthy development of the pharmaceutical industry
• What is the future of drug development in China?
Moderator: MarriettaWu, COO, Zai Laboratories, China
Panelists: Li Chen, CEO, Hua Medicine, China
Yin XiangWang, CEO&CSO, Zhejiang Beta Pharmaceuticals, China
Friedhelm Blobel, CEO, SciClone Pharmaceuticals, USA & China
Ming-Chu Hsu, ChairmanoftheBoard&CEO, TaiGen Biotechnology,Taiwan
WeikangTao, CEO,R&DCentre, Shanghai Hengrui Medicine, China
CHINA
REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.pharmaconchina.com
CONFERENCE DAY ONE TUESDAY 29 MARCH 2016
8.00 Registration & Morning Coffee
8.50 Welcome Address from IBC Asia & Get to KnowYour Peers
8.55 Chairperson’s Opening Remarks
KEYNOTEC-LEVELPANEL
DISCUSSION
9.50 Regulatory Updates and Changes in the Pharmaceutical Sector –What’s New,Trends and Impact
• Encouraging innovation and healthy development of the pharmaceutical industry
• Recent changes and updates in the pharmaceutical and medical device sectors –What to look out for?
• Meeting the growing clinical development demand and addressing approval delays and review process
• Enhancing your talent pool with the right experts to spearhead governmental oversight and supervision
Moderator: Lin Hong, AssociateDirector–RegulatoryAffairs,AsiaPacific,RussiaCIS(APAC)EstablishedPharmaceuticals, Abbott
Panelists: Dr Meir-ChyunTzou, SeniorResearcher&FormerDirectorofDivisionofPharmaceuticalAffairs, Taiwan Food and Drug Administration (TFDA),Taiwan
PANELDISCUSSION
China’s Pharmaceutical Market Outlook
10.30 Morning Networking & Refreshment Break
• Choose Your Sessions Across 3 Different Tracks with a GOLD PASS! •
CHINA
11.15
Chairperson’s Opening Remarks
GuChengming,VicePresident&theheadofmedicalaffairs
of Pfizer China & theChairmanMedicalAffairsGroup,
RDPAC, China
Chairperson’s Opening Remarks
Lin Hong, AssociateDirector–RegulatoryAffairs,Asia
Pacific,RussiaCIS(APAC)EstablishedPharmaceuticals,
Abbott
Chairperson’s Opening Remarks
EmmanuelVignal, Partner,GreaterChinaLeader,Fraud
Investigation&DisputesServices, EY
Current Clinical Trial Landscape
in Asia
Regulatory Updates to Improve
Drug Approval Timelines
China’s Healthcare Reform &
Compliance Frameworks
Execution Gap in Global Drug Development:The
Expectation And Current Position of Asia
Dan Paulson, VicePresident,GlobalClinicalDevelopment,
GroupHead,CardiometabolismRiskManagementand
Anti-infectives, Bayer HealthCare Pharmaceuticals,
China
UpdatesandChangesinPharmaceuticalRegulation
inTaiwan
DrMeir-ChyunTzou,SeniorResearcher&FormerDirector
ofDivisionofPharmaceuticalAffairs, Taiwan Food and
Drug Administration (TFDA)
The ABAC Risk is here to Stay – Key enforcement
Actions,Trends and Outlook for 2016 for the Life
Sciences Industry
EmmanuelVignal, Partner,GreaterChinaLeader,Fraud
Investigation&DisputesServices, EY
Accelerating the Global Drug Development
in China
Panelists:
Dan Paulson, VicePresident,GlobalClinicalDevelopment,
GroupHead,CardiometabolismRiskManagementandAnti-
infectives, Bayer HealthCare Pharmaceuticals, China
Ye Hua, SeniorVicePresident,ClinicalDevelopmentand
RegulatoryAffairs, Hutchison Medipharma, China
PANELDISCUSSION
E-Labelling & Packaging
Concomitant Review and Assessment of Package
Materials and Excipients
MsYanWANG,HeadofShanghaiFoodandDrugPackaging
MaterialControlCenter, Shanghai Municipal Food and
Drug Administration (SFDA)
China Health Care Reform – Big Business & Big Risk
RobertYouill, SeniorManagingDirector-GlobalRiskand
Investigations, FTI Consulting, China
Labelling
2.00
Latest Developments in Smart Labeling
FrankJaeger,ManagingDirector,Faubel&Co.,Germany
Building Compliance TeamsImplementation of an Innovative Labeling Hub
in Asia
Rie Matsui, Director,RegionalLabelingHeadforAsia,
Pfizer Japan
Building an Effective ComplianceTeam
12.40 Networking Lunch & MeetWithVIP Guests
VIPTable 1: Samantha Du,CEO,ChairmanoftheBoard, Zai Laboratories, China
VIPTable 2:WeikangTao, CEO,R&DCentre, Shanghai Hengrui Medicine, China
VIPTable 3:Yin XiangWang, CEO, Betta Pharmaceuticals, China
11.30
12.10
3. CHINA
REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.pharmaconchina.com
Best Practices in Clinical
Project Management
Pharmacovigilance
Data Analytics in Compliance
2.40
PANELDISCUSSION
Navigating the Quality Control of Drugs and Post-
Market Regulation
MsYanWANG,HeadofShanghaiFoodandDrugPackaging
MaterialControlCenter, Shanghai Food and Drug
Administration (SFDA)
MitigatingRisksandDemonstratingReturns
Through Data Analytics
Chi CHEN, Partner,FraudInvestigation&Disputes
Services, EY
Differentiating Regulations in Japan, Korea and
China on Postmarketing Drug Special Monitoring
3.20 Afternoon Networking & Refreshment Break
4.00
PANELDISCUSSION
Risk Management Planning toTackle Ethnic
Differences
Yu (Vivian) Sun, AssociateDirector,SafetySurveillance&
RiskManagement,ChinaResearch&DevelopmentCenter,
Pfizer Inc, China
The Compliance Landscape
and Approach in China
Karen Eryou, SeniorDirector,Corporate
ComplianceAPAC, UCB, China
4.40
CollaborationTacticsandOrganizationalStrategies
for Effective ClinicalTrial Budgeting
Panelists:
Wang Xiao Mei, Director,ClinicalOperations, TenNor
Therapeutics, China
GengWu, HeadofClinicalProjectManagementChina,
DevelopmentEastAsia&Network, UCB, China
DaisukeYamashita, AssociateDirector,StrategicProject
Management,TakedaDevelopmentCentreShanghai,
China
Quality Assurance and
Anti-Counterfeiting
Building a Quality Culture – Not just a Quality
Management System
Magnus Jahnsson, DirectorRegulatoryAffairs,
Pharmadule Morimatsu AB
Ensuring Sales, Marketing & Distribution
Programs Comply with Local Market
Practices
Lily Dong, SalesDirector, AstraZeneca, China
5.30 Chairperson’s Summary of the Day & End of Conference Day One
CONFERENCE DAY TWO WEDNESDAY 30 MARCH 2016
8.30 Morning Networking & Refreshment Break
• Choose Your Sessions Across 3 Different Tracks with a GOLD PASS! •
CHINA
8.55 Chairperson’s Opening Remarks
YiYang, Director,ASO(InternalMedicine),US
Pharmacovigilance, Sanofi, USA
Chairperson’s Opening Remarks
MaijaBurtmanis,HealthcareComplianceOfficer,AsiaPacific
MedicalSciences, Johnson & Johnson, Singapore
Regional Partnerships and
Coordination
9.00
PANELDISCUSSION
Driving Resilient Partnerships for Growth
MayWei Chun Fang, GlobalRegulatoryStrategist,
Bayer Healthcare Co Ltd China
Lin Hong, AssociateDirector–RegulatoryAffairs,
AsiaPacificRussiaCIS(APAC)Established
Pharmaceuticals, Abbott
Yuko Kikuchi, SeniorDirector–AsiaRegulatory
Affairs, Eisai Co Ltd
Third Party Compliance Program Assessment
MasoodAhmed,VicePresident,RegionalComplianceOfficer
Asia&JPAC, Sanofi Group, Singapore
MRCT Guidelines and
Product Development
KeepingDrugDevelopmentLeanwithInternational
Multi-Centre ClinicalTrials (IMCT) Guidelines
MayWei Chun Fang, GlobalRegulatoryStrategist,
Bayer Healthcare Co Ltd China
Choosing the Best Clinical
Development Pathway
Accelerating Biologics Drug Development in China
Gu Jin Ming, ExecutiveDirector,BiopharmaceuticalR&D,
Shanghai Hengrui Medicine, China
Impact of Recent CFDA Regulation on Cancer Drug
Development in China: Stakeholder Discussion
Moderator:
LiYan, VicePresident,HeadUnitPhysician,OncologyR&D,
GlaxoSmithKline Pharmaceuticals, USA
Panelists:
LiXu,CorporateVicePresidentandHeadofGlobalOncology,
Hengrui Co., China
Caichun Zhou, Professor, Shanghai Chest Hospital,
China
Xiao Xu, PresidentandCEO, Acea Co, USA &China
Hua Mu, SVP, WiXi Apptec, China
DajunYang, PresidentandCEO, Ascentage Pharma,
China
PANELDISCUSSION
Fostering an Ethical Culture
Steffanie Lim-Ho, VP,Ethics&Compliance,
Lilly, China
Transparent & Ethical Practices in
Local Markets
Chairperson’s Opening Remarks
Lin Hong, AssociateDirector–RegulatoryAffairs,Asia
Pacific,RussiaCIS(APAC)EstablishedPharmaceuticals,
Abbott
How to Make the SuccessfulTransition from
RegistrationTrials to Phase IV Studies?
Moderator:
Shell Li, FormerHeadofClinicalResearch, Boehringer
Ingelheim Pharmaceuticals,
ChiefMedicalOfficer,VicePresident,GlobalClinical
Development, HRYZ Biotech, China
Panelists:
Benny Li, GroupChiefMedicalOfficer, Hansoh
Pharmaceuticals, China
CristinaChang,CountryMedicalDirector,Celgene,Taiwan
YanGong,HeadofClinicalDevelopmentandMedicalAffairs
II, Boehringer Ingelheim Pharmaceuticals, China
4. CHINA
REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.pharmaconchina.com
Medical Device Regulations
Medical Device Regulations Overview in the Main
Established Markets: EU, USA, Japan, Canada and
Australia
ValTheisz, DirectorRegulatoryAffairs, Medical
Technology Association of Australia (MTAA)
9.40 Southeast Asia as a Key Platform for the
Acceleration of Global ClinicalTrial
Timelines for Chinese Pharma
JeffreyYablon, VicePresident,BusinessDevelopment,
GeneralManager–Asia, Indipharm, Malaysia
Streamlining Regulatory
Pathways & Strategies
Regulation on Fixed-Dose Combinations and
Co-Packaged Drugs
MayWei Chun Fang, GlobalRegulatoryStrategist,
Bayer Healthcare Co Ltd China
Tone at the Middle and Managing Patient
Relationship
RizaFaithYbanez,LegalandComplianceHead–Oncology
AsiaPacific,SouthAfrica, Novartis Asia Pacific
Pharmaceuticals Ptd Ltd, Singapore
10.20 Morning Networking & Refreshment Break
10.50 Clinical Development Pathway inTaiwan
Nathan Chen, VicePresident,ChiefMedical
Officer&HeadofGlobalMedicineDevelopment,
OBI Pharma,Taiwan
Best Practice Compliance
Strategies & Programs
Leapfrogging the Life-Cycle Management
Regulatory Pathways: How Efficient CanWe Get?
Yuko Kikuchi, SeniorDirector–AsiaRegulatoryAffairs,
Eisai Co Ltd Internal Compliance Program Assessment
JillDailey,AssistantGeneralCounsel,AsiaPacificCompliance
Lead, Pfizer, US
Strategic Partnerships &
Clinical Outsourcing
PANELDISCUSSION
11.40
Implementing Global Strategic Partnerships on a
RegionalLevel:ShapingtheFutureofFastandCost-
Effective ClinicalTrials in China
DejunTang, Head,Analytics,IntegratedInformation
SciencesChina, Novartis, China
Christina Bodurow, SeniorDirector,ExternalSourcing,
DevelopmentCenterofExcellence, Eli Lilly and Co, USA
YiYang, Director,ASO(InternalMedicine),USPV, Sanofi,
USA
TrackingDrugApprovalTimelines–GettingitRight
at Initial Regulatory Submissions
Ensuring Compliance During Business Development
Transactions & Partnership
Karen Choi, ComplianceDirector/CorporateCompliance,
Pfizer, Korea
12.10 Networking Lunch & MeetWithVIP Guests
VIPTable 1: Christina Bodurow, SeniorDirector,ExternalSourcing,DevelopmentCenterofExcellence, Eli Lilly and Co, USA
VIPTable 2:YiYang, Director,ASO(InternalMedicine),USPharmacovigilance, Sanofi, USA
VIPTable 3: Shell Li, ChiefMedicalOfficer,VicePresident,GlobalClinicalDevelopment, HRYZ Biotech, China
Good Clinical Practice (GCP)
and Site ManagemenT
1.30 Exploring Evolving Partnership Models and CRO
Selection Considerations in China
Christina Bodurow, SeniorDirector,ExternalSourcing,
DevelopmentCenterofExcellence, Eli Lilly and Co, USA
FDA 505(b)(2) Pathway For New Drug Application
LingyanLi,ProjectManager–SeniorPharmaceuticalAffairs
Scientist, Tasly Holding Group
How are Compliance Programs Evolving in China vs
the Region?
2.10
Leveraging the Sponsor Relationship Between KOL
and Sites for SuccessfulTrials in China
Yi (Gloria)Wang, ChiefChinaMedicalDevelopmentand
MedicalMonitorAsia, UnitedTherapeutics, China
E-CTDs and Dossier Submissions
Risk Management
Across Functions
Common Legal Issues and Risk Mitigation withThird
Parties
Tom Chan, HeadofLegalGreaterChina, Takeda (China)
Holdings Co. Ltd, China
3.10 Afternoon Networking & Refreshment Break
3.20
Clinical Data Quality
Quality Assurance Measures and Compliance in
Trials:EnsuringInspectionReadinessAcrossMultiple
Trial Sites
Liping Zhou, GlobalInspectionManager,R&DQuality,
Bayer HealthCare, China
Guoying Cao, DirectorofGCPOffice,HuashanHospital,
Fudan University, China
Tackling E-CTDs and Dossiers amidst Changing
Regulatory Developments
Jannie Ren, Director–ChinaHeadofPPLS(Publishing&
ProductLicenseSupport), Pfizer Regulatory Operation
Coordinating Risk Management
Across Functions
Coordinating Risk Management Across Functions
MaijaBurtmanis,HealthcareComplianceOfficer,AsiaPacific
MedicalSciences, Johnson & Johnson, Singapore
4.00
ImprovedProcessesandVendorOversightforClinical
Trials in China: Ensuring Quality, Compliance and
ROI for OutsourcedTrials
Intellectual Property
Laws & Legal Issues
IP and Patent Litigation
SowWeiWong, LegalCounsel, Takeda Global Research
& Development Centre (Asia), Singapore
4.45 Chairperson’s Summary of the Day & End of Conference
5. 29 - 30 March 2016
Grand Hyatt Shanghai
CHINA
Co-Located:
CHINA
Early Confirmed Companies Include:
REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.pharmaconchina.com
■ China/Hong Kong/Taiwan 60%
■ Japan/Korea 5%
■ Singapore 10%
■ Rest of Asia 10%
■ India/Middle East 5%
■ Australia/NZ 5%
■ US/Europe 5%
■ Pharma/Biopharma 60%
■ Government 5%
■ CROs 15%
■ Legal/Finance/Consultants 5%
■ Technology & Solution
Providers 10%
■ Research Institutes/Hospitals 5%
Why China is
Raiding Foreign
Companies At Dawn
~ Business Insider
Singapore,
January 2015
China's rigid
regulations hamper
bio-pharmaceutical
industry
~ Channel News Asia, July 2015
China's
Pharmaceutical
Future - Both
Complex and Growing
~ FDA Voice, June 2015
Navigate through a complex R&D environment?
Seek clarity on pharmaceutical regulations and
drug approvals in China?
Ensure your organization is operating compliantly?
Are
you
looking
to:
Are
you
looking
to:
If you answered yes to the above questions, then this conference is for you!
ThePharmaceuticalCongress(PharmaCon)Chinabringstogetheratimelyplatformtoexploredomesticpharmaceutical
research investments, developments and commercial operations.
WHO SHOULD ATTEND:WHO SHOULD ATTEND:
SPONSORSHIP OPPORTUNITIES
Would you like to raise your visibility in China’s pharmaceutical industry industry?
Could you benefit from showcasing your products & services before key industry players?
Are you seeking the lowest cost way of meeting a target audience of decision-makers?
If so, we can help you achieve your goals! Increase your reach through our extensive marketing campaign, targeted at your qualified business audience.
For information about placing your brand & profile top-of-mind to key buyers, contact Yvonne Leong, Business Development Manager ~
Tel: +65 6508 2489 or Email: yvonne.leong@ibcasia.com.sg
Abbott • Acea Co. • Allergan • Amgen • Astrazeneca • Bayer Healthcare Co Ltd China • Bayer Healthcare
Pharmaceuticals•Biocon•ZhejiangBettaPharmaceuticals•BoehringerIngelheimPharmaceuticals•Bristol-
Myers Squibb • Cardinal Health • Celgene • China Chamber of Commerce for Import and Export of Medicines
and Health Products (CCCMHPIE) • China Pharmaceutical Innovation and Research Development Association
(PhIRDA) • Eisai Co Ltd • Eli Lilly & Co. • Faubel & Co. • Fountain Medical Development • FTI Consulting •
Fudan University • GEC Risk Advisory LLC • GlaxoSmithKline Pharmaceuticals • Hengrui Co. • Hua Medicine
• Hutchison Medipharma • HYRZ Biotech • Indian Society for Clinical Research • Indipharm • Janssen
Pharmaceuticals • Johnson & Johnson • Jones Day • Lilly China • MedicalTechnology Association of Australia
(MTAA) • Novartis Pharmaceuticals (China) • Novartis Asia Pacific Pharmaceuticals • Novo Nordisk (China)
Pharmaceutical Co., Ltd • NUS East Asian Institute (EAI) • OBI Pharma Inc • PAREXEL International • Peking
UniversityHealthScienceCenter•Pfizer(China)Research&DevelopmentCoLtdCenter•PharmaduleMorimatsu
AB • R&G PharmaStudies • RDPAC • Sanofi-Aventis • SciClone Pharmaceuticals • Shanghai Chest Hospital
• Shanghai Food and Drug Administration (SFDA) • Shanghai Hengrui Pharmaceuticals • Shenzhen Chipscreen
Biosciences •TaiGen Biotechnology •Taiwan Food and Drug Administration (TFDA) •Takeda (China) Holdings
• Takeda Global Research & Development Centre (Asia) Pte Ltd • Takeda Pharmaceuticals • Tasly Holding
Group•TenNorTherapeutics•UCB•USChinaAnti-CancerAssociation•UnitedTherapeutics•ZaiLaboratories
Plus many more...
6. Email
register@ibcasia.com.sg
Fax
+65 6508 2407
Customer Service Hotline
+65 6508 2401
Web
www.pharmaconchina.com
DATA PROTECTION
CANCELLATIONS / SUBSTITUTION
IMPORTANT NOTE
REGNO.200108203N
• Payment by bankers draft or cheque in S$ or US$ should be
made in favour of “IBC Asia (S) Pte Ltd” and mailed to:
IBC Asia (S) Pte Ltd
c/o Informa Regional Business Services
111 Somerset Road, TripleOne Somerset #10-05
Singapore 238164
Attn: The Accounts Receivable Team
• Payment by bank transfer in S$ or US$ made payable to:
IBC Asia (S) Pte Ltd
A/C No.:147-059513-001 (S$)
A/C No.:260-457866-178 (US$)
The Hongkong and Shanghai Banking Corporation Limited
21 Collyer Quay, HSBC Building
Singapore 049320
Bank Swift Code: HSBCSGSG
Bank Code: 7232
• Payment by Credit Card (AMEX, VISA or MasterCard).
The best way to pay by credit card is through our secure
portal built into the website. To pay by phone please indicate
the contact name and details below and our Customer
Services Team will call within 24 hours to take payment.
Please do not send credit card information by email.
The personal information entered during your registration/order,
or provided by you, will be held on a database and may be
shared with companies in the Informa Group in the UK and
internationally. Occasionally, your details may be obtained from
or shared with external companies who wish to communicate
with you offers related to your business activities. If you do not
wish your details to be used for this purpose, please contact
our Database Department at Email: database@ibcasia.com.sg,
Tel: +65 6508 2400 or Fax: +65 6508 2408.
Should you be unable to attend, a substitute delegate is
welcome at no extra charge. Cancellations must be received in
writing at least 10 business days before the start of the event,
to receive a refund less 10% processing fee per registration.
The company regrets that no refund will be made available for
cancellation notifications received less than 10 business days
before the event.
Please quote the name of the delegate, event title and invoice
number on the advice when remitting payment. Bank charges
are to be deducted from participating organisations own accounts.
Please fax your payment details (copy of remittance advice,
cheque or draft to +65 6508 2407).
Attendance will only be permitted upon receipt of full payment.
Participants wishing to register at the door are responsible to
ensure all details are as published. IBC assumes no further
liability or obligation, beyond the refund of the paid registration
fee, in the event of postponement or cancellation by IBC.
5 EASY WAYS TO REGISTER
RESERVE YOUR PLACE TODAY!
CREDIT CARD PAYMENTS
The best way to pay by credit card is through our secure on-line registration process, simply log on to the website at
www.pharmaconchina.com and click “Register On-line”. If you would prefer to pay over the phone please complete the contact name
and details and our Customer Services Team will call within 24 hours to take payment. As we treat your credit card information in the
strictest confidence, please do not send payment details by email.
Department:
Email:
■ I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd
■ I am paying by bank transfer (copy attached)
■ Payment by Credit Card. (AMEX, VISA or MasterCard accepted)
PAYMENT METHOD
(Please tick)
Early Bird Rate
Register & pay on or
before 8 Jan 2016
Special Rate
Register & pay on or
before 26 Feb 2016
Normal Rate
Register & pay after
26 Feb 2016
FEE PER DELEGATE
❑ 2-Day Package USD 1,695 USD 1,895 USD 2,095 USD 2,295
DELEGATE 1 DETAILS
HOTEL INFORMATION
Grand Hyatt Shanghai, China
Jin Mao Tower, 88 Century Boulevard
Pudong, Shanghai 200121
Tel: +86 21 5049 1234 | Fax: +86 21 5049 8381
Contact Person: April Gu
Email: April.Gu@hyatt.com
PAYMENT TERMS
Payment must be received 10 business days prior to the event.
To take advantage of discounts with an expiry date, registration
and payment must be received by the cut-off date.
INTERNATIONAL COMPANIES – Global Headquarters Located Outside of Mainland China
DOMESTIC CHINA COMPANIES – Global Headquarters Located within Mainland China
GOLD PASS: Add USD 150 / CNY 1000 to upgrade to Gold Pass and have access to all 3 conferences.
Super Early Bird
Register & pay on or
before 27 Nov 2015
CNY 5,000 CNY 6,000 CNY 7,000 CNY 8,000
MAIL the attached registration form with your
cheque to
IBC Asia (S) Pte Ltd
c/o Informa Regional Business Services
111 Somerset Road,
TripleOne Somerset #10-05,
Singapore 238164
Name: Dr/Mr/Ms
Job Title:
Department:
Tel: Mobile No.:
Email:
Who is Head of your Department? Who is Head of Training?
Please photocopy for additional delegates
Credit card contact:
Direct phone number:
+65 6508 2401 register@ibcasia.com.sg www.pharmaconchina.com
CHINA
■ Yes! I/We will attend the Pharmacon China • 29 – 30 March 2016, Grand Hyatt Shanghai, China
■ Clinical Trials China ■■ Pharmaceutical Regulatory Summit China ■■ Pharmaceutical Compliance
■ GOLD PASS (All 3 Events)
❑ 2-Day Package
❑
Co-located events:
DELEGATE 2 DETAILS
Name: Dr/Mr/Ms
Job Title:
Department:
Tel: Mobile No.:
Email:
Main Business/Activity:
Postal Code:
Who is Head of your Department? Who is Head of Training?
Company Name:
Address:
REGISTER TODAY!
29 - 30 March 2016
Grand Hyatt Shanghai
CHINA